PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Mehilli, Julinda
TI  - ISAR-LEFT MAIN 2 Trial: Zotarolimus- versus Everolimus- Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions
DP  - 2012  01
TA  - MD Conference Express
PG  - 21--21
VI  - 12
IP  - 17
4099  - http://mdc.sagepub.com/content/12/17/21.short
4100  - http://mdc.sagepub.com/content/12/17/21.full
AB  - The original Drug-eluting Stents for Unprotected Left Main Stem Disease [ISAR-Left Main] study found no significant difference in outcomes for patients with unprotected left main coronary artery stenosis (uLMCS) who were treated with first generation paclitaxel-eluting versus sirolimus-eluting stents [Mehilli J et al. J Am Coll Cardiol 2009]. The objective of the current ISAR-LEFT MAIN 2 trial [NCT00598637] was to compare the performance of zotarolimus-eluting stent versus everolimus-eluting stent in patients with uLMCS lesions, using a noninferiority design.